MedTrace Logo

Lymphedema Treatment Registry

NCT04272372 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-09-07

No results posted yet for this study

Summary

Patients with breast cancer related lymphedema (clinical stage 0-2) will include in this study. Patients will take their demographic and clinical history and will evaluate with measurements of extremity volumes, body mass index, quality of life status and image studies (lymphoscintigraphy, Ultrasonography (USG), Indocyanine Green (ICG) Lymphograph or magnetic resonance imaging (MRI)) before and after the complete decongestive therapy. Outcome measurements such as limb volume, quality of life questionnaire and USG will repeat every 6,12,18, 24 months.

Conditions

  • Breast Cancer Lymphedema

Interventions

DRUG

Ketoprofen

PO and local therapy

Sponsors & Collaborators

  • Turkish Lymphedema Society

    collaborator UNKNOWN

  • The Breast Health Society, Turkey

    collaborator OTHER

  • Ege University

    lead OTHER

Principal Investigators

  • Atilla Soran · University of Pittsburgh Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-11-30
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04272372 on ClinicalTrials.gov